ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

TRB Trinity Biotech Plc

0.00
0.00 (0.00%)
- - Realtime Data
Share Name Share Symbol Market Type
Trinity Biotech Plc TG:TRB Tradegate Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.00 -

Rule 8 - Tribal Group plc

10/07/2003 11:56am

UK Regulatory


RNS Number:3946N
Merrill Lynch Investment ManagersLd
10 July 2003


FORM 8.1/8.3

Lodge with Company Announcements Office (which will publicise and copy to the
Panel). Use separate form for each class of securities in which dealings have
been made.

     Date of disclosure: 10th July, 2003

DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) AND 8.3 OF THE CITY CODE ON TAKE-OVERS
AND MERGERS

Date of dealing: 9th July, 2003

Dealing in:           Tribal Group Plc          (Name of Company)

(1) Class of securities: 5p Ordinary Shares      (eg ordinary shares):

(2)

Amount bought                Amount sold                      Price per unit

40,000                                                        325p

(3)     Resultant total of the same class owned or controlled
        (and percentage of class 1,513,876     (2.88%)

(4)     Party making disclosure : MERRILL LYNCH INVESTMENT MANAGERS LIMITED



(5)     EITHER (a) Name of purchaser/vendor (note 1)

            OR (b) If dealing for discretionary client(s), name of fund management
                   organisation:

                   MERRILL LYNCH INVESTMENT MANAGERS LIMITED



(6)     Reason for disclosure (Note 2)

     (a) associate of (i) offeror (Note 3)     XXX/NO

                     (ii) offeree company      XXX/NO

     Specify which category or categories of associate (1-8 overleaf)


             If category (8), explain      ....................................
        ... .......................................




             (b) Rule 8.3 (ie disclosure because of ownership or control of 1%
                 or more of the class of relevant securities dealt in)   YES/XX

Signed, for and on behalf of the party named in (4) above

(Also print name of signatory): Katey Neate


Telephone and extension number 020 7964 5641

        Note 1.     Specify owner, not nominee or vehicle company. If relevant,
        also identify controller of owner, eg where an owner normally acts on
        instructions of a controller.

        Note 2.     Disclosure might be made for more than one reason: if so,
        state all reasons.

        Note 3.     Specify which offeror if there is more than one.

        Note 4.     When an arrangement exists with any offeror, with the
        offeree company or with an associate of any offeror or of the offeree
        company in relation to relevant securities, details of such arrangement
        must be disclosed, as required by Note 6 on Rule 8.
        ........................................................................................


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

DCCBBLFFXDBEBBZ

1 Year Trinity Biotech Chart

1 Year Trinity Biotech Chart

1 Month Trinity Biotech Chart

1 Month Trinity Biotech Chart